Bright Minds Biosciences Files 6-K Report
Ticker: DRUG · Form: 6-K · Filed: Oct 16, 2024 · CIK: 1827401
| Field | Detail |
|---|---|
| Company | Bright Minds Biosciences INC. (DRUG) |
| Form Type | 6-K |
| Filed Date | Oct 16, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing-update, press-release, foreign-private-issuer
Related Tickers: BMBS
TL;DR
BMBS filed a 6-K with a press release on Oct 16, 2024. Check for updates.
AI Summary
Bright Minds Biosciences Inc. filed a Form 6-K on October 16, 2024, to report information for the month of October 2024. The filing includes a press release dated October 16, 2024, as Exhibit 99.1. The company is a foreign private issuer and will file its annual report under cover of Form 20-F.
Why It Matters
This filing provides an update from Bright Minds Biosciences Inc., potentially containing material information for investors regarding the company's operations or strategic direction.
Risk Assessment
Risk Level: low — This filing is a routine report (6-K) and does not appear to contain significant new financial or operational disclosures that would immediately alter risk.
Key Players & Entities
- BRIGHT MINDS BIOSCIENCES INC. (company) — Filer
- October 16, 2024 (date) — Filing date and press release date
- 001-40997 (other) — Commission File Number
- 19 VESTRY STREET (address) — Principal executive office and mail address
- New York, NY 10013 (address) — Principal executive office and mail address
- Form 20-F (document) — Annual report cover
- Exhibit 99.1 (document) — Submitted press release
FAQ
What is the primary purpose of this Form 6-K filing?
The Form 6-K is filed by Bright Minds Biosciences Inc. to report information for the month of October 2024, including a press release dated October 16, 2024.
What is the Commission File Number for Bright Minds Biosciences Inc.?
The Commission File Number for Bright Minds Biosciences Inc. is 001-40997.
What type of annual report cover does Bright Minds Biosciences Inc. use?
Bright Minds Biosciences Inc. indicates it files its annual reports under cover of Form 20-F.
What is the principal executive office address for the company?
The principal executive office address for Bright Minds Biosciences Inc. is 19 Vestry Street, New York, NY 10013.
What specific exhibit is submitted with this 6-K filing?
Exhibit 99.1, a Press Release dated October 16, 2024, is submitted with this 6-K filing.
Filing Stats: 148 words · 1 min read · ~1 pages · Grade level 11.6 · Accepted 2024-10-16 11:38:37
Filing Documents
- f6k_101624.htm (6-K) — 4KB
- exh_991.htm (EX-99.1) — 7KB
- 0001171843-24-005653.txt ( ) — 12KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Bright Minds Biosciences Inc. Date: October 16, 2024 /s/ Ryan Cheung Ryan Cheung Chief Financial Officer